A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy

American Journal of Transplantation

Volumn 9, Issue 8, 2009, Pages 1732-1741

  Aoyagi, T ^a   Yamashita, K ^a   Suzuki, T ^a   Uno, M ^a   Goto, R ^a   Taniguchi, M ^a   Shimamura, T ^a   Takahashi, N ^b   Miura, T ^b   Okimura, K ^b   Itoh, T ^c   Shimizu, A ^d   Furukawa, H ^a   Todo, S ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Costimulation blockade; Kidney transplantation; Monoclonal antibodies; Nonhuman primate

Indexed keywords

4D11 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; GRAFT SURVIVAL; KIDNEY TRANSPLANTATION; LEUKOCYTE; MAINTENANCE THERAPY; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD40 LIGAND; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MACACA FASCICULARIS; MALE; MODELS, ANIMAL; SIGNAL TRANSDUCTION;

EID: 67650966708     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02693.x     Document Type: Article

References (37)

1. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000 67 : 2 17.
2. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004 22 : 307 328.
3. de Vos AF, Melief MJ, van Riel D et al. Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys. Eur J Immunol 2004 34 : 3446 3455.
4. Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994 180 : 157 163.
5. Kawabe T, Naka T, Yoshida K et al. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1994 1 : 167 178.
6. Larsen CP, Alexander DZ, Hollenbaugh D et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996 61 : 4 9.
7. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996 381 : 434 438.
8. Yamashita K, Masunaga T, Yanagida N et al. Long-term acceptance of rat cardiac allografts on the basis of adenovirus mediated CD40Ig plus CTLA4Ig gene therapies. Transplantation 2003 76 : 1089 1096.
9. Nomura M, Yamashita K, Murakami M et al. Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. Transplantation 2002 73 : 1403 1410.
10. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999 5 : 686 693.
11. Montgomery SP, Xu H, Tadaki DK et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation 2002 74 : 1365 1369.
12. Xu H, Tadaki DK, Elster EA et al. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002 74 : 940 943.
13. Preston EH, Xu H, Dhanireddy KK et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 2005 5 : 1032 1041.
14. Schuler W, Bigaud M, Brinkmann V et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004 77 : 717 726. (Pubitemid 38366978)
15. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000 6 : 114.
16. Pidard D, Montgomery RR, Bennett JS, Kunicki TJ. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983 258 : 12582 12586.
17. Koyama I, Kawai T, Andrews D et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004 77 : 460 462. (Pubitemid 38209752)
18. Ankersmit HJ, Roth GA, Moser B et al. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: Implication of therapy-induced in vivo thrombocytopenia. Am J Transplant 2003 3 : 754 759.
19. Haanstra KG, Ringers J, Sick EA et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003 75 : 637 643.
20. Pearson TC, Trambley J, Odom K et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002 74 : 933 940.
21. Adams AB, Shirasugi N, Jones TR et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005 174 : 542 550.
22. Imai A, Suzuki T, Sugitani A et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007 84 : 1020 1028.
23. Knapp LA, Lehmann E, Hennes L, Eberle ME, Watkins DI. High-resolution HLA-DRB typing using denaturing gradient gel electrophoresis and direct sequencing. Tissue Antigens 1997 50 : 170 177.
24. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723. (Pubitemid 29082898)
25. Solez K, Colvin RB, Racusen LC et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 7 : 518 526.
26. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006 6 (5 Pt 1 876 883.
27. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003 92 : 1041 1048.
28. Kirk AD, Knechtle SJ, Sollinger HW, Vincenti F, Stecher S, Nadeau K. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001 1 (1 Suppl S191.
29. Miura T, Okimura K, Takahashi N, Kataoka S. Pharamacological and toxicological studies of a fully human antibody (4D11) against human CD40 in human samples in vitro and non-human primates in vivo. Am J Transplant 2005 5 (11 Suppl 420.
30. Kirk AD. Induction immunosuppression. Transplantation 2006 82 : 593 602.
31. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005 5 : 443 453.
32. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 353 : 770 781.
33. Haanstra KG, Sick EA, Ringers J et al. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005 79 : 1623 1626.
34. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003 12 : 19 28.
35. Hale G, Swirsky DM, Hayhoe FG, Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1983 1 : 321 334.
36. Andre P, Prasad KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002 8 : 247 252.
37. Crow AR, Leytin V, Starkey AF, Rand ML, Lazarus AH. CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost 2003 1 : 850 852.